CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
about
CIViC databaseH19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-β-Catenin Signaling in Colorectal Cancer.DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer.Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases.Favorable control of advanced colon adenocarcinoma with severe bone marrow metastasis: A case report.New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targetsCDX2: Linking Cell and Patient Fates in Colon CancerCHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status.HEROD: a human ethnic and regional specific omics database.TCF7L1 Modulates Colorectal Cancer Growth by Inhibiting Expression of the Tumor-Suppressor Gene EPHB3Assessment of clinically related outcomes and biomarker analysis for translational integration in colorectal cancer (ACROBATICC): study protocol for a population-based, consecutive cohort of surgically treated colorectal cancers and resected colorecThe characterization of an intestine-like genomic signature maintained during Barrett's-associated adenocarcinogenesis reveals an NR5A2-mediated promotion of cancer cell survival.The prognostic yield of biomarkers harvested in chemotherapy-naive stage II colon cancer: can we separate the wheat from the chaff?hERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy.Dual specificity phosphatase 5 is a novel prognostic indicator for patients with advanced colorectal cancer.Investigating the prognostic value of KOC (K homology domain containing protein overexpressed in cancer) overexpression after curative intent resection of pancreatic ductal adenocarcinoma.Construction and analysis of tissue microarrays in the era of digital pathology: a pilot study targeting CDX1 and CDX2 in a colon cancer cohort of 612 patients.Rapidly cycling Lgr5+ stem cells are exquisitely sensitive to extrinsic dietary factors that modulate colon cancer risk.BRAFV600E cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis.Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions.Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer.Adjuvant Therapy Trials.Transcriptional Regulator CNOT3 Defines an Aggressive Colorectal Cancer Subtype.Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.Time-dependent and nonlinear effects of prognostic factors in nonmetastatic colorectal cancer.From tumour heterogeneity to advances in precision treatment of colorectal cancer.Current and future biomarkers in the treatment of colorectal cancer.Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer.Chemotherapy Use and Survival Among Young and Middle-Aged Patients With Colon Cancer.Cancer predisposition syndromes: lessons for truly precision medicine.Longitudinal monitoring of gene expression in ultra-low-volume blood samples self-collected at home.Colon cancer subtypes: concordance, effect on survival and selection of the most representative preclinical models.What We Know About Stage II and III Colon Cancer: It's Still Not Enough.TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype.Cytokeratin 20 positive cells in blood of colorectal cancer patients as an unfavorable prognostic marker.Differential expression of CK20, β-catenin, and MUC2/5AC/6 in Lynch syndrome and familial colorectal cancer type XComputer-aided biomarker discovery for precision medicine: data resources, models and applications.SHP2 associates with nuclear localization of STAT3: significance in progression and prognosis of colorectal cancer.Homeobox protein CDX2 as a prognostic biomarker in solid malignancies: a meta-analysis.
P2860
Q27612411-931DCC00-2DC8-4F3F-AE8E-C1C8B56D2765Q30836400-6C4F53DE-668C-4E5F-92AF-477B58E2AD20Q30837199-1B610175-A212-41CA-A23E-450D65432D8FQ31138564-E21E66BA-F688-432B-8CC1-0EE072319206Q33437194-661D70E0-BCB5-45F1-84E4-92F9BB54C0DFQ33731804-049F6F82-0784-47D2-8D40-3E9AA8940C7AQ33872642-A5A4FD64-89FA-4039-AE85-F6242E277A2AQ36340540-B3E95C1D-61F7-4338-8DC9-152C72543FEBQ36345775-D3DD8AA6-E268-4A8B-8834-734A0612B666Q36382897-BDD9B38F-01FC-4135-B167-8F19C3F97A01Q37030861-6DAC2E5D-6050-4F69-B521-47E9FD769DEDQ37054795-8C068C69-7681-4799-872D-F5F4D900A450Q37227732-1BE0F26D-9D9B-48BC-B433-3A1E86604703Q37256316-16590131-B1C2-490C-9CB9-C346E4F7BF20Q37354154-C6D73D09-2687-4957-83D8-AF6908755468Q37382545-BE3171C7-6E5F-41B0-AFF9-2978C770FEAAQ37525354-19096365-64D0-4EB3-88E6-D5697CF47E5DQ37601727-841B1DF3-EA39-4F76-A60B-F0F8C163ECD6Q37603293-76DE7C5C-D90C-460A-ADB6-B618E22360D4Q37608879-CEFCB61F-1D3E-4F6D-B006-EFDEF12273DCQ37673704-04089FF3-81AE-459D-8E9C-39FA61CF0414Q37689098-2C42F594-BACE-4FC3-A910-0639D4636D8BQ37698462-0C555DDB-D38D-4965-8BE8-202611026281Q38289993-04E12E02-4022-40DD-9FD4-B1CC1748266BQ38661008-E79474E6-12CB-4611-ACE5-D6B23513D9A1Q38679554-89674B7E-25C0-4B7C-BB3A-A2D8A27C8D93Q38786707-21D682E1-E683-46E6-8F8F-BB7DBF19EE2CQ38787244-2BC9DB2A-890B-40D6-8C6A-08CD9746C8C9Q38995724-E40115A6-405A-48BC-8812-C57C9156EE52Q38999686-122E5E66-8F36-4F64-9378-4A49F6CB5BC9Q39012229-53F66A6B-DB1A-4095-B2C8-073C93939CCBQ39069291-181644AC-4079-4157-AD4F-E99326E430F5Q39184305-93F50CC0-CE57-4082-9E69-C046F2FE1C8BQ39306576-164CADAA-4C1A-4B83-87F6-E549833D4EFCQ39739202-36060D12-B923-4679-9C98-027EFB1D4950Q40769679-0F8456F5-E7D2-4D5D-A5DA-D016B4AB1E29Q41438646-8A416A6B-EF01-4185-B20E-26F50EAD12F6Q45943371-F839F230-1A59-4A59-82B6-8962D622D200Q47097561-434537C9-F2DD-451D-894E-E92CD25F5C06Q47097887-93AAA38F-910C-48FA-8D9C-C5ECD93F41AA
P2860
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
@ast
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
@en
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
@nl
type
label
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
@ast
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
@en
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
@nl
altLabel
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
@en
prefLabel
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
@ast
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
@en
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
@nl
P2093
P2860
P50
P3181
P356
P1476
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
@en
P2093
Dalong Qian
Debashis Sahoo
Erna Forgó
George A Fisher
Greg Yothers
Jacqueline Hutchison
Michael F Clarke
Nate Wilcox-Fogel
Norman Wolmark
P2860
P304
P3181
P356
10.1056/NEJMOA1506597
P407
P577
2016-01-21T00:00:00Z